Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
122 hedge funds and large institutions have $826M invested in Genomic Health, Inc. in 2015 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 59 increasing their positions, 23 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
157% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 23
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
21% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $1.1M
9% more funds holding
Funds holding: 112 → 122 (+10)
8% less capital invested
Capital invested by funds: $901M → $826M (-$74.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$33.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.5M |
| 3 |
Renaissance Technologies
New York
|
+$6.5M |
| 4 |
Goldman Sachs
New York
|
+$4.66M |
| 5 |
Millennium Management
New York
|
+$4.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTC
North Tide Capital
Boston,
Massachusetts
|
-$45.8M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$30.8M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$8.98M |
| 4 |
TA
Teachers Advisors
New York
|
-$3.02M |
| 5 |
BC
Broadfin Capital
New York
|
-$2.29M |
GHDX Hedge Fund Activity: Q2 2015 in Review
122 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q2 2015, worth a combined $826M — down 8.3% from $901M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GHDX positions and 5 closed out — a net gain of 10 holders — while 59 added to existing stakes and 23 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $33.4M. The largest seller was North Tide Capital, exiting entirely with an estimated $45.8M sold.
- 122 institutional investors held Genomic Health, Inc. (GHDX) as of Q2 2015, up from 112 in Q1 2015.
- Funds reported $826M of Genomic Health, Inc. stock for Q2 2015, down 8.3% quarter-over-quarter.
- 15 funds opened new Genomic Health, Inc. positions in Q2 2015 and 5 closed out, a net change of +10 holders.
- The largest Genomic Health, Inc. buyer in Q2 2015 was Deerfield Management, an estimated $33.4M added.
- The largest Genomic Health, Inc. seller in Q2 2015 was North Tide Capital, an estimated $45.8M sold.
Based on aggregated 13F filings for Q2 2015.